Marty Driscoll's guest appearances

Marty Driscoll

Empowered Patient Podcast

Mark Allen

David Katz

Rosalind Picard

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

OwlTail

Marty Driscoll, CEO of Spring Bank Pharmaceuticals, discusses treatments for the hepatitis B virus, a disease suffered by 250 million people globally who are chronically infected with the hepatitis B virus. Marty talks about what a functional cure for chronically infected patients means, and what Spring Bank is doing to help those affected. Spring Bank is developing a new oral drug named inarigivir that is a selective immunomodulator/encapsidation inhibitor. Inarigivir could become a key component of a future safe and simple combination treatment in an effort to substantially increase functional cure rates for patients with chronic hepatitis B and reduce their need for daily drugs. @springbankpharm #HBV #HepatitisB  #Functionalcure #inarigivir Spring Bank Pharmaceuticals

Marty Driscoll, CEO of Spring Bank Pharmaceuticals, discusses treatments for the hepatitis B virus, a disease suffered by 250 million people globally who are chronically infected with the hepatitis B virus. Marty talks about what a functional cure for chronically infected patients means, and what Spring Bank is doing to help those affected. Spring Bank is developing a new oral drug named inarigivir that is a selective immunomodulator/encapsidation inhibitor. Inarigivir could become a key component of a future safe and simple combination treatment in an effort to substantially increase functional cure rates for patients with chronic hepatitis B and reduce their need for daily drugs. @springbankpharm #HBV #HepatitisB  #Functionalcure #inarigivir <a href="http://springbankpharm.com" rel="noopener nofollow" target="_blank">Spring Bank Pharmaceuticals</a>

Pursuing a Potential Functional Cure for Chronic Hepatitis B with Marty Driscoll Spring Bank Pharmaceuticals